TPPP2 Antibody

What is TPPP2 and what tissues express it?

TPPP2 is one of three paralogs of mammalian TPPP proteins involved in regulating microtubule dynamics. Unlike its family members, TPPP2 shows highly tissue-specific expression limited to the male reproductive system. RT-PCR analysis has confirmed that TPPP2 mRNA is exclusively expressed in testis and epididymis, with no detection in heart, spleen, lung, kidney, brain, uterus, ovary, or liver .

TPPP2 expression is developmentally regulated, with mRNA levels sharply increasing during the third post-natal week in mice, coinciding with spermatid formation. In testicular tissue, TPPP2 is restrictively expressed at stages IV-VIII of the seminiferous epithelial cycle, corresponding to elongating spermatids at steps 15-16 of spermiogenesis when the morphology of spermatids has basically formed . In the epididymis, immunofluorescence analysis reveals TPPP2 localization specifically in the middle piece of the sperm tail, corresponding to the mitochondrial sheath region .

What applications are TPPP2 antibodies suitable for?

TPPP2 antibodies have been validated for multiple research applications:

Researchers should optimize dilutions for each specific experimental setup, as antibody performance may vary across different tissue preparations and fixation methods . TPPP2 antibodies have been successfully applied to human, mouse and rat tissues, with cross-reactivity observed in several mammalian species .

What is the cellular localization of TPPP2 in normal tissues?

In testicular tissue, TPPP2 shows stage-specific expression in elongating spermatids at steps 15-16 of spermiogenesis, which are critical phases for establishing sperm morphology . Immunohistochemical analysis reveals that TPPP2 expression in testis is confined to stages IV-VIII of the seminiferous epithelial cycle .

In mature sperm, TPPP2 localizes specifically to the middle piece of the sperm tail, which contains the mitochondrial sheath responsible for energy production . This localization pattern correlates with TPPP2's functional role in sperm motility and ATP production.

Unlike other TPPP family members that strongly associate with microtubule structures, TPPP2 shows a more homogeneous cytosolic distribution when expressed in cell lines. In A-431 cells, immunofluorescent staining shows positivity in both nucleus and cytoplasm . This distinct distribution pattern reflects TPPP2's unique functional properties compared to other TPPP paralogs .

How can TPPP2 antibodies be used to investigate male infertility?

TPPP2 antibodies provide valuable tools for investigating oligoasthenozoospermia and other male fertility disorders through several methodological approaches:

• Comparative expression analysis: Antibody-based assays can reveal differential TPPP2 expression patterns between fertile and infertile individuals. Research has shown that TPPP2 is overexpressed 2.2x in low-fertility buffalo sperm , while upregulated in high-fertility bulls , suggesting complex species-specific roles.

• Functional inhibition studies: Anti-TPPP2 antibodies can be used experimentally to inhibit TPPP2 function in vitro. Studies show that adding anti-TPPP2 antibody (20 μg/mL) to sperm samples significantly reduces motility and ATP content in both human and mouse sperm compared to control IgG treatment . This approach helps establish causal relationships between TPPP2 and sperm function.

• Fertilization assays: Following TPPP2 antibody inhibition, researchers can assess in vitro fertilization rates to determine reproductive outcome impacts. Data shows significantly reduced fertilization rates in antibody-treated samples compared to controls .

• Structure-function analysis: Immunolocalization studies using TPPP2 antibodies can correlate protein distribution patterns with functional parameters such as mitochondrial integrity, ATP production, and motility characteristics .

These methodologies are particularly valuable when studying molecular mechanisms underlying oligoasthenozoospermia, as studies with TPPP2 knockout mice demonstrated significantly decreased sperm count and motility resembling this clinical condition .

What methodological considerations should be made when validating the specificity of TPPP2 antibodies?

Validating TPPP2 antibody specificity is critical due to potential cross-reactivity with other TPPP family members. The literature indicates some antibodies recognize human TPPP2 but also cross-react with mouse TPPP1, TPPP2, and TPPP3 at varying percentages (59%, 65%, and 85%, respectively) . Multiple validation approaches should be employed:

• Western blot analysis: Test antibodies against recombinant TPPP proteins and tissue lysates known to differentially express TPPP family members. A specific TPPP2 antibody should detect a single 19 kDa band in testicular/sperm lysates but not in brain tissue (which predominantly expresses TPPP1) .

• Tissue specificity testing: TPPP2 is exclusively expressed in male reproductive tissues, TPPP1 in brain (particularly in oligodendrocytes), and TPPP3 in musculoskeletal tissues . Antibodies should be tested across these tissues to confirm specificity.

• Knockout controls: Tissues from TPPP2 knockout mice provide ideal negative controls for antibody validation . Absence of staining in knockout samples confirms specificity.

• Peptide competition assays: Pre-incubating the antibody with immunizing peptide before staining should eliminate specific signals. The immunogen information provided for commercial antibodies (e.g., "recombinant fragment corresponding to 7-160 AA of human TPPP2" ) can guide peptide design.

• Multiple antibodies approach: Using antibodies targeting different epitopes (N-terminal versus C-terminal) can increase confidence in staining patterns . Concordant results with multiple antibodies suggest specific detection.

These validation steps are essential before undertaking detailed TPPP2 expression studies or functional analyses, especially in contexts where multiple TPPP family members might be present.

What experimental approaches can be used to study the role of TPPP2 in mitochondrial function of sperm?

Since TPPP2 localizes to the middle piece of sperm containing mitochondria and affects ATP production, several experimental approaches can elucidate its role in mitochondrial function:

• ATP quantification assays: Measure ATP content in sperm after TPPP2 inhibition with antibodies. Studies show significantly decreased ATP levels following incubation with anti-TPPP2 antibodies (20 μg/mL), correlating with reduced motility .

• Mitochondrial membrane potential analysis: Utilize fluorescent dyes sensitive to mitochondrial membrane potential (e.g., JC-1, TMRM) to assess mitochondrial function in relation to TPPP2 expression or inhibition.

• Ultrastructural analysis: Transmission electron microscopy can examine mitochondrial morphology in TPPP2 knockout models, which have demonstrated impaired mitochondrial structure .

• Co-localization studies: Immunofluorescence with TPPP2 antibodies alongside mitochondrial markers (TOM20, cytochrome C) can reveal spatial relationships and potential interactions .

• Protein interaction analysis: Immunoprecipitation with TPPP2 antibodies followed by mass spectrometry can identify interacting partners involved in mitochondrial function. Research has already identified interactions between TPPP2 and GAPDHS (a sperm-specific glycolytic enzyme) .

• Mitochondrial respiration measurements: Oxygen consumption rate analysis in sperm samples with normal versus altered TPPP2 expression provides functional data on mitochondrial respiration.

• Genetic complementation studies: Reintroduce wild-type or mutant TPPP2 into knockout models to determine which protein domains are essential for mitochondrial function and sperm motility.

These methodological approaches provide complementary data on how TPPP2 influences mitochondrial function in sperm, potentially revealing therapeutic targets for male infertility treatments.

How do researchers interpret contradictory findings regarding TPPP2 expression in different fertility studies?

The literature contains apparently contradictory findings regarding TPPP2 expression and fertility. For example, TPPP2 is overexpressed 2.2x in low-fertility buffalo sperm but upregulated in high-fertility bulls . Resolving such contradictions requires systematic analysis:

• Species-specific differences: Despite significant homology among TPPP2 proteins from different species, functional differences may exist. Comparative sequence analysis and structure-function studies can reveal species-specific adaptations.

• Context-dependent functions: TPPP2 may have multiple roles depending on cellular context or developmental stage. Upregulation could be compensatory in some situations but pathological in others.

• Methodological variations: Studies may use different techniques for measuring TPPP2 (mRNA vs. protein levels, different antibodies). Standardizing methodologies by using validated antibodies with consistent protocols enhances comparability.

• Expression threshold effects: Optimal TPPP2 expression likely falls within a specific range—both insufficient and excessive levels may impair fertility through different mechanisms.

• Post-translational modifications: TPPP2, like other family members, may undergo phosphorylation affecting its function . Antibodies detecting total TPPP2 versus modified forms might yield different results.

• Interacting protein networks: TPPP2 functions within networks including GAPDHS, SSMEM1, TEX33, TSSK4, and TRIM42 . Variations in these interaction partners across species could modify TPPP2's functional impact.

What considerations should be made when analyzing TPPP2 immunostaining patterns in oligoasthenozoospermia samples?

When analyzing TPPP2 immunostaining in oligoasthenozoospermia samples, researchers should consider several methodological factors:

• Subcellular localization assessment: Normal TPPP2 localization is in the middle piece of sperm tails . Researchers should look for altered distribution patterns, such as displacement from this region or abnormal aggregation.

• Quantitative analysis: Both immunofluorescence intensity measurements and western blot quantification should be performed to determine whether TPPP2 levels are altered compared to fertile controls.

• Heterogeneity evaluation: Not all sperm within a sample may show identical TPPP2 patterns. The percentage of sperm with normal versus abnormal TPPP2 expression/localization should be quantified.

• Correlation with functional parameters: TPPP2 immunostaining patterns should be correlated with specific sperm parameters:

  • Motility (particularly curvilinear velocity, which shows high correlation with TPPP2 levels)

  • ATP content (which correlates with TPPP2 function)

  • Mitochondrial integrity (which may be compromised in TPPP2-deficient sperm)

• Co-staining approaches: Combining TPPP2 antibodies with markers for mitochondria (e.g., TOM20), sperm structure, or other functional proteins provides contextual information about potential mechanisms.

• Control selection: Age-matched fertile controls are essential for valid comparisons, as TPPP2 expression may vary with age or other demographic factors.

• Technical considerations: Consistent sample preparation, antibody concentrations, and imaging parameters are crucial for reliable analysis across specimens.

These methodological considerations help ensure that TPPP2 immunostaining data from oligoasthenozoospermia samples yields meaningful insights into potential pathophysiological mechanisms.

How can researchers differentiate between direct effects of TPPP2 inhibition and secondary effects on sperm motility?

Distinguishing primary from secondary effects of TPPP2 inhibition requires systematic experimental approaches:

• Time-course experiments: Following TPPP2 inhibition with antibodies, researchers should measure multiple parameters (ATP levels, mitochondrial function, motility patterns) at different time points to establish the sequence of events. Studies show that after 30 minutes of antibody treatment, both reduced ATP and impaired motility were observed .

• Dose-response analysis: Experiments using different antibody concentrations (2, 8, and 20 μg/mL) revealed that only the highest concentration (20 μg/mL) significantly affected motility . This suggests a threshold effect and helps distinguish direct from indirect effects.

• Pathway-specific inhibitors: Combining TPPP2 inhibition with inhibitors of specific downstream pathways can reveal mechanistic dependencies.

• Functional specificity assessment: The finding that TPPP2 antibody treatment affected motility and ATP content but not capacitation or acrosome reaction suggests specific rather than general effects on sperm function . This specificity supports direct rather than non-specific effects.

• Genetic rescue experiments: In TPPP2 knockout models, introducing wild-type or mutated TPPP2 can help identify which domains are directly responsible for specific functions.

• Comparative inhibition approaches: Different inhibition methods (antibodies, genetic knockdown, small molecules) targeting TPPP2 should ideally produce similar primary effects if they are direct consequences of TPPP2 inhibition.

• In vitro reconstitution: Using purified components to reconstruct TPPP2 function can establish direct molecular mechanisms independent of cellular complexity.

These methodological approaches help establish causal relationships between TPPP2 inhibition and observed functional changes in sperm, informing more precise understanding of TPPP2's role in male fertility.

What are the optimal fixation and preparation methods for TPPP2 immunodetection in sperm samples?

Optimal detection of TPPP2 in sperm requires careful sample preparation:

For immunohistochemistry on tissue sections:

• Fixation: Paraffin embedding following formalin fixation has been successfully used for TPPP2 detection in human testicular tissues .

• Antigen retrieval: May be necessary to expose epitopes masked during fixation.

• Antibody dilution: 1/100-1/200 has been reported as effective for IHC-P applications .

For immunofluorescence on sperm:

• Fixation: While not explicitly detailed in the literature for TPPP2, mild fixation (4% paraformaldehyde, 10-15 minutes) preserves structure while maintaining antigenicity.

• Permeabilization: Given TPPP2's localization in the middle piece of the sperm tail , adequate permeabilization (0.1-0.2% Triton X-100) is necessary for antibody access without disturbing subcellular structures.

• Blocking: Thorough blocking (3-5% BSA or normal serum) reduces background staining.

• Primary antibody: Dilutions of 1/100 have been effective for immunofluorescence applications .

• Washing: Multiple PBS washes between steps minimize background.

For cultured cells:

• Fixation/permeabilization: PFA/Triton X-100 treatment has been successfully used for TPPP2 detection in cell lines .

• Antibody concentration: 1/100 dilution has shown effective results in ICC/IF applications .

For all applications:

• Include appropriate positive controls (testicular tissue, sperm samples) and negative controls (non-reproductive tissues, no-primary antibody controls).

• Validate antibody specificity using methods described in section 2.2.

• Standardize all protocols across experimental samples to ensure comparability.

These methodological details ensure reliable and reproducible TPPP2 detection in sperm and testicular samples.

What controls should be included when using TPPP2 antibodies for western blotting of testicular tissues?

Robust western blot analysis of TPPP2 requires comprehensive controls:

• Positive tissue controls:

  • Adult testis tissue (known to express TPPP2)

  • Epididymal sperm samples

  • Gonadal tissue lysates (shown effective in western blot applications)

• Negative tissue controls:

  • Brain tissue (expresses TPPP1 but not TPPP2)

  • Heart, liver, or kidney tissues (shown to lack TPPP2 expression)

• Technical controls:

  • Loading control: Housekeeping proteins (β-actin, GAPDH) to normalize protein loading

  • Molecular weight marker: To verify the expected 19 kDa band size for TPPP2

• Antibody validation controls:

  • Recombinant TPPP2 protein as positive control

  • TPPP2 knockout mouse tissue as negative control

  • Pre-adsorption control (antibody pre-incubated with immunizing peptide)

  • Isotype control (same concentration of non-specific IgG)

• Sample preparation controls:

  • Fresh versus frozen tissue comparisons to assess protein degradation effects

  • Different extraction buffer compositions to optimize TPPP2 solubilization

• Developmental controls:

  • Testis samples from different developmental stages, given that TPPP2 expression increases sharply during the third post-natal week in mice

• Dilution series:

  • Antibody titration to determine optimal concentration (typically 1/250-1/500 for western blot)

  • Protein load titration to ensure detection is within linear range

These comprehensive controls ensure specificity, sensitivity and reproducibility when analyzing TPPP2 expression in testicular tissues and sperm samples.

What methodological approaches can be used to study TPPP2 interaction with microtubules and other cytoskeletal elements?

Although TPPP2 shows weaker affinity for microtubules than other family members , investigating its cytoskeletal interactions remains important for understanding spermiogenesis and sperm function:

• Co-sedimentation assays: Mixing purified TPPP2 with polymerized microtubules, followed by centrifugation to separate bound and unbound fractions. This approach has revealed that TPPP2's affinity for tubulin/microtubules is an order of magnitude weaker than other TPPP paralogs .

• Immunofluorescence co-localization: Double-labeling sperm or testicular tissue with TPPP2 antibodies and cytoskeletal markers (α-tubulin, actin). Quantitative co-localization analysis using Pearson's or Mander's coefficients provides statistical assessment of association.

• Proximity ligation assay (PLA): This technique can detect protein-protein interactions with high sensitivity, useful for detecting potentially transient or weak TPPP2-cytoskeletal interactions in situ.

• Co-immunoprecipitation: Using TPPP2 antibodies for immunoprecipitation followed by western blotting for cytoskeletal proteins can identify interaction partners. Studies have already identified several interacting partners including GAPDHS and TSSK4 .

• In vitro microtubule polymerization assays: Unlike other family members, TPPP2 lacks significant microtubule bundling activity , but may still influence microtubule dynamics in subtle ways that can be measured with polymerization kinetics assays.

• Structure-function analysis: Creating truncated or mutated forms of TPPP2 to identify domains responsible for any cytoskeletal interactions, validating with the techniques above.

• Electron microscopy: Immunogold labeling for TPPP2 combined with electron microscopy can precisely localize the protein in relation to microtubule structures in sperm with nanometer resolution.

• Live-cell imaging: Using fluorescently tagged TPPP2 constructs to observe its dynamics in relation to labeled cytoskeletal elements during spermiogenesis or in cultured cells.

These methodological approaches provide complementary data on TPPP2's relationship with cytoskeletal elements, contributing to understanding its role in sperm structure and function.